Neuberger Berman Group
SGMO

Neuberger Berman Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Neuberger Berman Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,587
Closed -$7.09K – 1965
2024
Q1 		$7.09K Buy
+10,587
New +$7.68K ﹤0.01% 1824
2023
Q4 		– Sell
-14,281
Closed -$8.57K – 1910
2023
Q3 		$8.57K Buy
+14,281
New +$15.3K ﹤0.01% 1793
2019
Q1 		– Sell
-14,917
Closed -$171K – 1604
2018
Q4 		$171K Sell
14,917
-3,298
-18% -$41K ﹤0.01% 1508
2018
Q3 		$309K Buy
+18,215
New +$277K ﹤0.01% 1424
2018
Q1 		– Sell
-61,000
Closed -$1M – 1732
2017
Q4 		$1M Buy
61,000
+40,000
+190% +$595K ﹤0.01% 1206
2017
Q3 		$315K Buy
+21,000
New +$232K ﹤0.01% 1403

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Neuberger Berman Group's SGMO Position: Q2 2024 in Review

Neuberger Berman Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2024, closing a stake of 10,587 shares — an estimated $7.09K sold.

Neuberger Berman Group first reported a position in SGMO in Q3 2017 and held it in 6 quarters. The position peaked at $1M in Q4 2017. 129 funds tracked by Wall St. Rank hold SGMO as of Q2 2024.

  • Neuberger Berman Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 10,587 SANGAMO THERAPEUTICS INC shares in Q2 2024, an estimated $7.09K.
  • Neuberger Berman Group first reported a position in SANGAMO THERAPEUTICS INC in Q3 2017 and held it in 6 quarters.
  • Neuberger Berman Group's SANGAMO THERAPEUTICS INC position peaked at $1M in Q4 2017.
  • 129 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2024.

Based on Neuberger Berman Group's 13F filing for Q2 2024, filed 13 Aug 2024.